BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/26/2019 11:08:19 AM | Browse: 729 | Download: 1003
|
Received |
|
2019-03-22 01:58 |
|
Peer-Review Started |
|
2019-03-25 02:24 |
|
To Make the First Decision |
|
2019-05-23 06:00 |
|
Return for Revision |
|
2019-06-03 03:53 |
|
Revised |
|
2019-06-12 13:46 |
|
Second Decision |
|
2019-06-20 06:01 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-06-27 17:05 |
|
Articles in Press |
|
2019-06-27 17:05 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-07-26 05:58 |
|
Publish the Manuscript Online |
|
2019-07-26 11:08 |
ISSN |
1948-5182 (online) |
Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Review |
Article Title |
Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Amr Dokmak, Mohammad Almeqdadi, Hirsh Trivedi and Sandeep Krishnan |
ORCID |
|
Funding Agency and Grant Number |
|
Corresponding Author |
Sandeep Krishnan, MBBS, MD, Chief Physician, Doctor, Division of Gastroenterology, St. Elizabeth’s Medical Center, 736 Camrbridge st., Brighton, MA 02135, United States. sandeep.krishnan@steward.org |
Key Words |
Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Sodium-glucose cotransporter 2 inhibitors; Liver cirrhosis; Diabetes; |
Core Tip |
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the Western world. NAFLD is associated with obesity and insulin resistance. Weight loss is the cornerstone of therapy with no other proven pharmacologic therapy, Sodium-glucose co-transporter 2 (SGLT2) inhibitors may play a role in preventing and treating NAFLD. SGLT2 inhibitors reduce hepatic steatosis, steatohepatitis, and fibrosis in patients with NAFLD. |
Publish Date |
2019-07-26 11:08 |
Citation |
Dokmak A, Almeqdadi M, Trivedi H, Krishnan S. Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease. World J Hepatol 2019; 11(7): 562-573 |
URL |
https://www.wjgnet.com/1948-5182/full/v11/i7/562.htm |
DOI |
https://dx.doi.org/10.4254/wjh.v11.i7.562 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345